Life Sciences

Our expertise

A focused strategy

A focused strategy

The Life Sciences team of Edmond de Rothschild Investment Partners invests in companies active in human health through the dedicated BioDiscovery venture capital funds raised since 2000. It has contributed to the development of 52 companies, of which 16 have gone public via IPO or reverse merger and 14 have been acquired through trade sales.

Our approach

A long-term vision and innovative opportunities

Relying on a minority shareholding, the team supports the development of the company and its products for 2 to 6 years, and then sells its shares, most of the time to a large company which commercializes the products after the development is completed.

With close to € 450 million under management dedicated to the Life Sciences sector, Edmond de Rothschild Investment Partners leads the financing rounds of companies based mainly in Europe, and active in one of the following three areas: therapeutic products, medical devices and molecular diagnostics.

More specifically the activity of Life Sciences team at Edmond de Rothschild Investment Partners is distinguished by the following characteristics:

  • Lead investor with a significant shareholding (15-25%)
  • Strong involvement of the team, systematically hold Board positions in portfolio companies
  • Support in the development of products from pre-clinical proof of concept, or prototype (medical devices), to the proof of concept in humans, or commercialisation (medical devices).

Our team

gilles-nobecourt GILLES NOBÉCOURT
Partner
raphale-wisniewski RAPHAEL WISNIEWSKI
Partner
sofia-ioannidou SOFIA IOANNIDOU
Investment Director
Guillem Laporta GUILLEM LAPORTA
Analyst
Rémi Spagnol
           

REMI  SPAGNOL
Analyst
OLIVIER LITZKA
Partner
THIERRY HERCEND
Venture Partner
Naveed Siddiqi NAVEED SIDDIQI
Partner, Life Sciences
Mathieu Piéronne MATHIEU PIÉRONNE
Analyst 
 Hélène BREMAUD HELENE  BREMAUD
Asset Management Assistant 

Our portfolio

  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Small molecule for the treatment of progressive multiple sclerosis MedDay Pharmaceuticals
    April 2016
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of optimized therapeutic antibodies for the treatment of cancer GAMAMABS
    December 2015
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Small molecules as a therapeutic treatment for RSV infection ReViral
    September 2015
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Phytic acid for the treatment of cardiovascular calcification Sanifit
    September 2015
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of neurostimulation devices for the treatment of Cluster Headache Autonomic Technologies Inc.
    May 2015
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital New approach to increasing the affectivness and safety of currenthly marketed Alzheimer's CHASE Pharmaceuticals
    May 2014
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Implantable neurostimulation technology for the treatment of chronic pain Axonics
    March 2014
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Anti-inflammatory peptides for the treatment of sepsis Inotrem
    February 2014
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Capital increase Platform of scaffold proteins oriented against intracellular targets in oncology Complix
    June 2013
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Capital Increase Development of novel treatments to combat multi drug-resistant bacterial infections Allecra
    April 2013
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of inhibitors of enzymes involved in oxydative stress GenKyoTex
    May 2011
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development and commercialisation of a new mobile diabetes management system Cellnovo
    January 2011
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of small molecules for the treatment of Type 2 diabetes Poxel
    June 2010
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Mocules for the treatment of inflammatory diseases Tobira Therapeutics
    December 2009
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of innovative molecule drugs for the treatment of neurodegenerative diseases Probiodrug
    October 2009
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development and commercialization of a new ultrasound system for diagnosis of cancers SuperSonic Imagine
    October 2008
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of immunotherapeutics for treatment of cervix cancer caused by HPV Genticel
    August 2008
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of a non-invasive valve replacement technology JenaValve
    August 2007
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of a new class of aptamers as therapeuticals Noxxon
    April 2007
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Commercialisation of orthopedic implants with an innovative sale traceability tool Implanet
    February 2007
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development and commercialisation of a low X ray doses 3D imaging device EOS Imaging
    November 2005
  • GetAlt(<%# Eval("ReferencesVignette") %>
    Augmentation de capital Development of in vitro diagnostic tests for early detection of tumor biomarkers MDxHealth
    October 2005
/
Need more information?

Contact us

Hélène Brémaud
Hélène Brémaud

+ 33 1 40 17 27 69